Transcutaneous canine breast cancer detection in Tunisia: a pilot study.

Cancer Cancer screening test Diagnosis Smell Working dogs

Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
30 Jan 2024
Historique:
received: 09 02 2023
accepted: 01 11 2023
medline: 31 1 2024
pubmed: 31 1 2024
entrez: 30 1 2024
Statut: epublish

Résumé

Breast cancer in Tunisia is often diagnosed at a late stage with long delay in time to consultation and to diagnosis.The aim of this study is to estimate the sensitivity and specificity of the transcutaneous breast cancer detection by canine olfactionin Tunisian women and to identify the potential confounding factors. This is a diagnostic case control study that took place from October 2021 to November 2022 in the Department of Medical Oncology at the University Hospital Farhat Hached of Sousse and in the security and training dog center located in Sousse (K9 Dog Center Security & Training). A two-year-old male Belgian Malinois was trained to detect breast cancer on skin secretion samples in compresses that had been worn overnight by women on their breast and then a double-blind testing was performed. There was no contact between women and the dog. From the mentioned responses of the dog, four parameters were calculated: sensitivity, specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV). Two hundred women were included in this trial: 100 breast cancer (BC) patients recruited from Farhat Hached University Hospital of Sousse and 100 healthy volunteers (HV).The calculated sensitivity was 84% (95% CI 78-89%) and the calculated specificity was 81% (95% CI 75-86%). The calculated predictive values were: PPV = 83,51% (95% CI 78,37-88,65%) and NPV = 81,55% (95% CI 76.17-86.93%). In the multivariate study, only four confounding factors of test's sensitivity were retained: age (OR = 1.210 [95% CI = 1.085-1.349]; p = 0.001), history of diabetes(OR = 0.017 [95% CI = 0.001-0.228]; p = 0.002), sampling at hospital (OR = 0.010 [95% CI = 0.003-0.464]; p = 0.010) and testing during chemotherapy courses (OR = 0.034 [95% CI = 0.003-0.404]; p = 0.007).For test's specificity, we retained the three following confounding factors: age (OR = 1,104 [95% CI = 1.021-1.195]; p = 0.014), history of benign mastopathy (OR = 0.243 [95% CI = 0.074-0.805]; p = 0.021)and history of arterial hypertension (OR = 0.194 [95% CI = 0.053-0.707]; p = 0.013). This is a pilot study that opens new avenues in developing a reliable cancer diagnostic tool that integrates the dog's olfactory ability to detect breast cancer using a transcutaneous sampling method. It could be a pre-test to select patients who are eligible to a screening mammogram, especially in low-income countries where there is no national mammography screening program. PACTR. PACTR202201864472288, registration date 11/01/2022.

Sections du résumé

BACKGROUND BACKGROUND
Breast cancer in Tunisia is often diagnosed at a late stage with long delay in time to consultation and to diagnosis.The aim of this study is to estimate the sensitivity and specificity of the transcutaneous breast cancer detection by canine olfactionin Tunisian women and to identify the potential confounding factors.
METHODS METHODS
This is a diagnostic case control study that took place from October 2021 to November 2022 in the Department of Medical Oncology at the University Hospital Farhat Hached of Sousse and in the security and training dog center located in Sousse (K9 Dog Center Security & Training). A two-year-old male Belgian Malinois was trained to detect breast cancer on skin secretion samples in compresses that had been worn overnight by women on their breast and then a double-blind testing was performed. There was no contact between women and the dog. From the mentioned responses of the dog, four parameters were calculated: sensitivity, specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV).
RESULTS RESULTS
Two hundred women were included in this trial: 100 breast cancer (BC) patients recruited from Farhat Hached University Hospital of Sousse and 100 healthy volunteers (HV).The calculated sensitivity was 84% (95% CI 78-89%) and the calculated specificity was 81% (95% CI 75-86%). The calculated predictive values were: PPV = 83,51% (95% CI 78,37-88,65%) and NPV = 81,55% (95% CI 76.17-86.93%). In the multivariate study, only four confounding factors of test's sensitivity were retained: age (OR = 1.210 [95% CI = 1.085-1.349]; p = 0.001), history of diabetes(OR = 0.017 [95% CI = 0.001-0.228]; p = 0.002), sampling at hospital (OR = 0.010 [95% CI = 0.003-0.464]; p = 0.010) and testing during chemotherapy courses (OR = 0.034 [95% CI = 0.003-0.404]; p = 0.007).For test's specificity, we retained the three following confounding factors: age (OR = 1,104 [95% CI = 1.021-1.195]; p = 0.014), history of benign mastopathy (OR = 0.243 [95% CI = 0.074-0.805]; p = 0.021)and history of arterial hypertension (OR = 0.194 [95% CI = 0.053-0.707]; p = 0.013).
CONCLUSION CONCLUSIONS
This is a pilot study that opens new avenues in developing a reliable cancer diagnostic tool that integrates the dog's olfactory ability to detect breast cancer using a transcutaneous sampling method. It could be a pre-test to select patients who are eligible to a screening mammogram, especially in low-income countries where there is no national mammography screening program. PACTR.
ORG IDENTIFIER UNASSIGNED
PACTR202201864472288, registration date 11/01/2022.

Identifiants

pubmed: 38291377
doi: 10.1186/s12885-023-11599-3
pii: 10.1186/s12885-023-11599-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151

Informations de copyright

© 2024. The Author(s).

Références

Cancer (IARC) TIA for R on. Global Cancer Observatory. 2022. https://gco.iarc.fr/ . Accessed 7 Dec 2022.
Mahjoub N, Salem KB, Mokrani A, Mansouri H, Achour L, Chraiet N, et al. Profil épidémiologique et anatomopathologique du cancer du sein dans la région du Nord-Ouest de la Tunisie Epidemiological and anatomopathological profil of breast cancer in the region of North-West of Tunisia. Tunis Med. 2021;99:8.
Belaid I, Fatma LB, Ezzairi F, Hochlaf M, Chabchoub I, Gharbi O, et al. Trends and current challenges of breast cancer in Tunisia: a retrospective study of 1262 cases with survival analysis. Breast J. 2018;24:846–8.
doi: 10.1111/tbj.13062 pubmed: 29781116
Landolsi A, Gahbiche S, Chaafii R, Chabchoub I, Fatma LB, Hochlef M, et al. Causes du Retard diagnostic du cancer du sein chez la femme Tunisienne : Série de 160 patientes au centre Tunisien. Tunis Med. 2010;88:4.
Ben Fatma L, Belaid I, Said N, Gahbiche S, Hochlef M, Chabchoub I, et al. What could be the reasons of late diagnosis of breast cancer in Tunisia? Tunis Med. 2018;96:665–71.
pubmed: 30746659
Guest C, Harris R, Sfanos KS, Shrestha E, Partin AW, Trock B, et al. Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer. PLoS One. 2021;16:e0245530.
doi: 10.1371/journal.pone.0245530 pubmed: 33596212 pmcid: 7888653
Bauër P, Leemans M, Audureau E, Gilbert C, Armal C, Fromantin I. Remote medical scent detection of cancer and infectious diseases with dogs and rats: a systematic review. Integr Cancer Ther. 2022;21:15347354221140516.
doi: 10.1177/15347354221140516 pubmed: 36541180 pmcid: 9791295
Willis CM, Church SM, Guest CM, Cook WA, McCarthy N, Bransbury AJ, et al. Olfactory detection of human bladder cancer by dogs: proof of principle study. BMJ. 2004;329:712.
doi: 10.1136/bmj.329.7468.712 pubmed: 15388612 pmcid: 518893
McCulloch M, Jezierski T, Broffman M, Hubbard A, Turner K, Janecki T. Diagnostic accuracy of canine scent detection in early- and late-stage lung and breast cancers. Integr Cancer Ther. 2006;5:30–9.
doi: 10.1177/1534735405285096 pubmed: 16484712
Gordon RT, Schatz CB, Myers LJ, Kosty M, Gonczy C, Kroener J, et al. The use of canines in the detection of human cancers. J Altern Complement Med. 2008;14:61–7.
doi: 10.1089/acm.2006.6408 pubmed: 18199013
Cornu J-N, Girardet C, Cussenot O. Des chiens dressés pour une nouvelle méthode de dépistage des cancers ? Prog En Urol - FMC. 2010;20:F135–8.
doi: 10.1016/j.fpurol.2010.04.004
Piqueret B, Bourachot B, Leroy C, Devienne P, Mechta-Grigoriou F, d’Ettorre P, et al. Ants detect cancer cells through volatile organic compounds. iScience. 2022;25.
Kure S, Iida S, Yamada M, Takei H, Yamashita N, Sato Y, et al. Breast cancer detection from a urine sample by dog sniffing: a preliminary study for the development of a new screening device, and a literature review. Biology. 2021;10:517.
doi: 10.3390/biology10060517 pubmed: 34200793 pmcid: 8230505
Pirrone F, Albertini M. Olfactory detection of cancer by trained sniffer dogs: a systematic review of the literature. J Vet Behav. 2017;19:105–17.
doi: 10.1016/j.jveb.2017.03.004
Thuleau A, Gilbert C, Bauër P, Alran S, Fourchotte V, Guillot E, et al. A New Transcutaneous Method for Breast Cancer Detection with Dogs. Oncology. 2019;96:110–3.
doi: 10.1159/000492895 pubmed: 30278460
du Sert NP, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLOS Biol. 2020;18:e3000410.
doi: 10.1371/journal.pbio.3000410
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.
doi: 10.2307/2529310 pubmed: 843571
Willis CM, Britton LE, Harris R, Wallace J, Guest CM. Volatile organic compounds as biomarkers of bladder cancer: sensitivity and specificity using trained sniffer dogs. Cancer Biomark. 2011;8:145–53.
doi: 10.3233/CBM-2011-0208
Horvath G, Järverud G af K, Järverud S, Horváth I. Human ovarian carcinomas detected by specific odor. Integr Cancer Ther. 2008;7:76–80.
doi: 10.1177/1534735408319058 pubmed: 18505901
Ehmann R, Boedeker E, Friedrich U, Sagert J, Dippon J, Friedel G, et al. Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon. Eur Respir J. 2012;39:669–76.
doi: 10.1183/09031936.00051711 pubmed: 21852337
Walczak M, Jezierski T, Górecka-Bruzda A, Sobczyńska M, Ensminger J. Impact of individual training parameters and manner of taking breath odor samples on the reliability of canines as cancer screeners. J Vet Behav. 2012;7:283–94.
doi: 10.1016/j.jveb.2012.01.001
Elliker KR, Sommerville BA, Broom DM, Neal DE, Armstrong S, Williams HC. Key considerations for the experimental training and evaluation of cancer odour detection dogs: lessons learnt from a double-blind, controlled trial of prostate cancer detection. BMC Urol. 2014;14:22.
doi: 10.1186/1471-2490-14-22 pubmed: 24575737 pmcid: 3945616
Amundsen T, Sundstrøm S, Buvik T, Gederaas OA, Haaverstad R. Can dogs smell lung cancer? First study using exhaled breath and urine screening in unselected patients with suspected lung cancer. Acta Oncol. 2014;53:307–15.
doi: 10.3109/0284186X.2013.819996 pubmed: 23957595
Taverna G, Tidu L, Grizzi F, Torri V, Mandressi A, Sardella P, et al. Olfactory system of highly trained dogs detects prostate cancer in urine samples. J Urol. 2015;193:1382–7.
doi: 10.1016/j.juro.2014.09.099 pubmed: 25264338
Buono MJ, McKENZIE BK, Kasch FW. Effects of Ageing and Physical Training on the Peripheral Sweat Production of the Human Eccrine Sweat Gland. Age Ageing. 1991;20:439–41.
doi: 10.1093/ageing/20.6.439 pubmed: 1776594
Goodman JI. Diabetic anhidrosis. Am J Med. 1966;41:831–5.
doi: 10.1016/0002-9343(66)90040-4 pubmed: 5922894
Adams D, Cauquil C, Lozeron P. Dysautonomies des neuropathies périphériques. Presse Médicale. 2012;41:1128–36.
doi: 10.1016/j.lpm.2012.05.030 pubmed: 23021660
Quintero-Atencio J, Vásquez-León H, Pino-Quintero LM. Association of sweat sodium with arterial-blood pressure. N Engl J Med. 1966;274:1224–8.
doi: 10.1056/NEJM196606022742202 pubmed: 5935420
Wang C, Sun B, Guo L, Wang X, Ke C, Liu S, et al. Volatile Organic Metabolites Identify Patients with Breast Cancer, Cyclomastopathy, and Mammary Gland Fibroma. Sci Rep. 2014;4:5383.
doi: 10.1038/srep05383 pubmed: 24947160 pmcid: 4064322
Kumar S, Huang J, Abbassi-Ghadi N, Mackenzie HA, Veselkov KA, Hoare JM, et al. Mass spectrometric analysis of exhaled breath for the identification of volatile organic compound biomarkers in esophageal and gastric adenocarcinoma. Ann Surg. 2015;262:981–90.
doi: 10.1097/SLA.0000000000001101 pubmed: 25575255
Tacher S, Quignon P, Rimbault M, Dreano S, Andre C, Galibert F. Olfactory receptor sequence polymorphism within and between breeds of dogs. J Hered. 2005;96:812–6.
doi: 10.1093/jhered/esi113 pubmed: 16251519

Auteurs

Imtinene Belaid (I)

Faculté de Médecine de Sousse, Farhat Hached University Hospital, Department of Medical Oncology, Association de Recherche et d'Information sur le Cancer du Centre Tunisien (ARIC), Université de Sousse, 4000, Sousse, Tunisia. belaid_im@hotmail.fr.

Mohamed Fedy Baya (MF)

Faculté de Médecine de Sousse, Farhat Hached University Hospital, Department of Medical Oncology, Association de Recherche et d'Information sur le Cancer du Centre Tunisien (ARIC), Université de Sousse, 4000, Sousse, Tunisia.

Saif Ben Ayed (S)

K9 Dog Security and Training Center, Sousse, Tunisia.

Ali Ben Ayed (A)

K9 Dog Security and Training Center, Sousse, Tunisia.

Jihen Maatoug (J)

Faculté de Médecine de Sousse, Farhat Hached University Hospital, Department of Epidemiology, Université de Sousse, 4000, Sousse, Tunisia.

Nawel Zommit (N)

Faculté de Médecine de Sousse, Farhat Hached University Hospital, Department of Epidemiology, Université de Sousse, 4000, Sousse, Tunisia.

Mohamed Anas Trabelsi (MA)

Veterinary Clinic, 4054, Bouhsina, Sahloul, Tunisia.

Noureddine Ben Chida (N)

National School of Veterinary Medicine, Veterinary Research Institute, Tunis, Tunisia.

Hedi Khairi (H)

Faculté de Médecine de Sousse, Farhat Hached University Hospital, Department of Gynecology, Université de Sousse, 4000, Sousse, Tunisia.

Leila Ben Fatma (L)

Faculté de Médecine de Sousse, Farhat Hached University Hospital, Department of Medical Oncology, Association de Recherche et d'Information sur le Cancer du Centre Tunisien (ARIC), Université de Sousse, 4000, Sousse, Tunisia.

Imene Chabchoub (I)

Faculté de Médecine de Sousse, Farhat Hached University Hospital, Department of Medical Oncology, Association de Recherche et d'Information sur le Cancer du Centre Tunisien (ARIC), Université de Sousse, 4000, Sousse, Tunisia.

Nouha Ammar (N)

Faculté de Médecine de Sousse, Farhat Hached University Hospital, Department of Medical Oncology, Association de Recherche et d'Information sur le Cancer du Centre Tunisien (ARIC), Université de Sousse, 4000, Sousse, Tunisia.

Rym Bourigua (R)

Faculté de Médecine de Sousse, Farhat Hached University Hospital, Department of Medical Oncology, Association de Recherche et d'Information sur le Cancer du Centre Tunisien (ARIC), Université de Sousse, 4000, Sousse, Tunisia.

Makrem Hochlaf (M)

Faculté de Médecine de Sousse, Farhat Hached University Hospital, Department of Medical Oncology, Association de Recherche et d'Information sur le Cancer du Centre Tunisien (ARIC), Université de Sousse, 4000, Sousse, Tunisia.

Faten Ezzaari (F)

Faculté de Médecine de Sousse, Farhat Hached University Hospital, Department of Medical Oncology, Association de Recherche et d'Information sur le Cancer du Centre Tunisien (ARIC), Université de Sousse, 4000, Sousse, Tunisia.

Slim Ben Ahmed (S)

Faculté de Médecine de Sousse, Farhat Hached University Hospital, Department of Medical Oncology, Association de Recherche et d'Information sur le Cancer du Centre Tunisien (ARIC), Université de Sousse, 4000, Sousse, Tunisia.

Classifications MeSH